Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 10, 2020 16:01 ET | Source: Soleno Therapeutics

Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2020 Financial Results

REDWOOD CITY, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
June 29, 2020 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics Added to Russell 3000® Index

REDWOOD CITY, Calif., June 29, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
June 26, 2020 16:01 ET | Source: Soleno Therapeutics

Soleno Therapeutics Announces Closing of $57.5 Million Public Offering of Common Stock, Including the Full Exercise of Underwriters’ Option to Purchase Additional Shares

REDWOOD CITY, Calif., June 26, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel...
June 24, 2020 08:31 ET | Source: Soleno Therapeutics

Soleno Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock

REDWOOD CITY, Calif., June 24, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq:SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics...
June 23, 2020 16:01 ET | Source: Soleno Therapeutics

Soleno Therapeutics Announces Proposed Public Offering of Common Stock

REDWOOD CITY, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel...
June 08, 2020 16:01 ET | Source: Soleno Therapeutics

Soleno Therapeutics Announces Top-line Results from Phase III Trial of DCCR for Treatment of Prader-Willi Syndrome

Study Did Not Meet Statistical Significance for Primary Endpoint, but Showed Significant Improvements in Prespecified Subgroup with Severe Hyperphagia Significant Positive Changes Also Seen in Two of...
May 12, 2020 16:01 ET | Source: Soleno Therapeutics

Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2020 Financial Results

REDWOOD CITY, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...
April 23, 2020 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics Announces Publication Evaluating Potential Role of Activating ATP-Sensitive Potassium Channel in Treatment of Hyperphagic Obesity

Paper Published in Peer-Reviewed Journal, Genes, as Part of Special Supplement on Genetics of Prader-Willi Syndrome (PWS) DCCR is the first K-ATP Channel activator being developed for PWS Company...
March 11, 2020 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics to Present at the 30th Annual Oppenheimer Healthcare Conference

REDWOOD CITY, Calif., March 11, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
March 04, 2020 16:05 ET | Source: Soleno Therapeutics

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2019 Financial Results

REDWOOD CITY, Calif., March 04, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...